Valuation : Silence Therapeutics plc

Market Cap 596M 808M 695M 653M 1.12B 76.83B 1.13B 7.74B 3.01B 38.96B 3.03B 2.97B 129B P/E 2026 *
-19.9x
P/E 2027 * -16.4x
Enterprise Value 463M 627M 540M 507M 869M 59.67B 876M 6.01B 2.34B 30.26B 2.35B 2.3B 100B EV / Sales 2026 *
1,425x
EV / Sales 2027 * 562x
Free-Float
69.35%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Silence Therapeutics plc

1 day-0.78%
1 week-0.19%
Current month+26.45%
1 month+26.45%
3 months+103.14%
6 months+134.16%
Current year+118.17%
1 week 13.09
Extreme 13.0896
13.99
1 month 10.32
Extreme 10.32
17.58
Current year 4.19
Extreme 4.19
17.58
1 year 4.19
Extreme 4.19
17.58
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 30/11/2025
Director of Finance/CFO 54 31/01/2022
Chief Tech/Sci/R&D Officer - 31/12/2020
Director TitleAgeSince
Director/Board Member 63 20/06/2018
Chairman 72 31/12/2003
Director/Board Member 65 04/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
06/07/26 Sell 865,112 0.6105%
02/01/26 Free

Chief Financial Officer

375,000 0.2646%
02/01/26 Free

Director

90,000 0.0635%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-0.19%+178.09%+49.04% 808M
-1.23%-1.91%+0.98%+17.94% 50.47B
-1.91%-3.71%+415.36%+499.71% 44.56B
-0.73%-0.32%+41.18%+16.52% 43.08B
-2.47%-3.93%+7.63%+72.18% 41.7B
-0.94%-1.77%+18.34%+46.84% 33.21B
-1.94%-4.99%+24.45%+117.96% 16.77B
+6.95%+5.36% - - 16.28B
+0.25%-0.98%+11.63%+27.62% 14.58B
-1.35%-3.68%+78.36%+39.06% 13.92B
Average -0.40%-1.00%+86.22%+98.54% 27.54B
Weighted average by Cap. -0.87%-1.04%+89.05%+121.24%

Financials

2026 *2027 *
Net sales 325K 440K 379K 356K 610K 41.87M 614K 4.22M 1.64M 21.23M 1.65M 1.62M 70.3M 751K 1.02M 876K 822K 1.41M 96.77M 1.42M 9.74M 3.79M 49.07M 3.82M 3.74M 162M
Net income -41.45M -56.17M -48.36M -45.41M -77.87M -5.34B -78.42M -538M -209M -2.71B -211M -206M -8.97B -66.28M -89.82M -77.33M -72.61M -125M -8.55B -125M -860M -335M -4.33B -337M -330M -14.35B
Net Debt -133M -180M -155M -146M -250M -17.16B -252M -1.73B -672M -8.7B -677M -662M -28.81B -174M -236M -203M -191M -327M -22.44B -329M -2.26B -879M -11.38B -885M -866M -37.68B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
31/08/26 US$13.27 -1.15% 146,581
28/08/26 US$13.42 -0.22% 539,704
27/08/26 US$13.45 -0.59% 283,674
26/08/26 US$13.53 -1.02% 301,700
25/08/26 US$13.67 +2.86% 645,032
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.42USD
Average target price
33.00USD
Spread / Average Target
+145.90%

Quarterly revenue - Rate of surprise